Dieter Falkenburg
Chief Executive Officer at Novoplant GmbH
Profile
Dieter Falkenburg has been Chief Executive Officer of Novoplant GmbH since May 2004.
He joined ASTA Medica in 1990 as Manager of International Business Development.
He was appointed as Vice President of Business Development for MPB Cologne and Executive Vice President of Business Development for Direvo AG in 1999.
Dr. Falkenburg received a PhD from Ruprecht Karls University, Heidelberg.
Dieter Falkenburg active positions
| Companies | Position | Start |
|---|---|---|
Novoplant GmbH
 Novoplant GmbH Agricultural Commodities/MillingProcess Industries Novoplant GmbH develops and provides veterinary medicines. It produces antibodies and antibody fragments in plants for veterinary use to fight intestinal pathogens. It received a license for the development and commercialization of therapeutic antibodies as feed components for use in veterinary medicine. It will use MorphoSys’s HuCAL GOLD technology to generate antibodies against viruses, parasites and pathogenic microorganisms. The addition of such antibodies to animal feed stock may offer protection against infectious diseases in the respective animal’s gastro-intestinal tract. The company was founded in 1998 and is headquartered in Gatersleben, Germany. | Chief Executive Officer | - |
Former positions of Dieter Falkenburg
| Companies | Position | End |
|---|---|---|
| ASTA Medica Oncology | Corporate Officer/Principal | - |
Training of Dieter Falkenburg
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Novoplant GmbH
Novoplant GmbH Agricultural Commodities/MillingProcess Industries Novoplant GmbH develops and provides veterinary medicines. It produces antibodies and antibody fragments in plants for veterinary use to fight intestinal pathogens. It received a license for the development and commercialization of therapeutic antibodies as feed components for use in veterinary medicine. It will use MorphoSys’s HuCAL GOLD technology to generate antibodies against viruses, parasites and pathogenic microorganisms. The addition of such antibodies to animal feed stock may offer protection against infectious diseases in the respective animal’s gastro-intestinal tract. The company was founded in 1998 and is headquartered in Gatersleben, Germany. | Process Industries |
| ASTA Medica Oncology |
- Stock Market
- Insiders
- Dieter Falkenburg
